Keynote Speaker:
Harry P. Erba, MD, PhD
Leukemia program director at Duke Cancer Institute and chair of SWOG Leukemia Committee
Education includes research fellowships at Harvard and Brigham and Women’s Hospital, PhD and MD at Stanford University
Dr. Erba is a dedicated clinical investigator having participated in dozens of clinical trials, his research focuses on the development of novel therapies for hematologic malignancies. Drawing on his vast knowledge and experience, he will discuss clinical trial dilemmas, and the pathway for new therapeutics from concept through FDA approval.
New Features for Attendees!
Meet the Expert: An opportunity to discuss toxicities and challenging treatment choices with nationally recognized experts.
Clinical Quandaries: Do you have a unique or unusually challenging hematologic malignancy patient? Patients may present with atypical symptoms, have particularly challenging co-morbidities, or have failed multiple lines of treatment. A new feature of Duke Debates 2024, Clinical Quandaries Panel, provides an exciting opportunity to have featured ‘Duke Debate’ speakers in the field of hematologic malignancy discuss, review, and provide real world advice on the management of your own challenging hematologic malignancy patient.
To submit a case to be reviewed at the Duke Debates Hematologic Malignancies 2024 Conference, please click the link and provide relevant information. You will be notified by email when your case is accepted and will be discussed.